[Squirrel Hunter]

AXIM can wait as long as they want to provide the updates. The notes are not converted until the company issues shares in response to a conversion request. It seems like as long as they hold the Derivative liability for insufficient shares rather than converting the variable notes they can delay reporting the dilution as long as they want. At least until the 10K but they could probably continue after the 10K with just a note in the narrative. .

[Blue Skys]

Day 22 of AXIM's stealth rally has drawn to a close. Its trading like it is in a quiet period. Seems to make sense with the huge OS increase reported on Silver Flume and nothing new released on OTC Markets. JH should be releasing a lot of news soon. So many possibilities with potentially large quantities of shares procured by third parties but not disclosed because they have not been delivered due to the share shortage. Is Versea increasing their ownership stake in AXIM? Is one of the families tickers securing ownership of Versea to take it public? Why was the NPTX ticker allowed to be revoked? Did the family fail to acquire voting control or is there more? We are well past three months since the draft of the shareholder letter was disclosed. I was thinking 3 months for resolution but apparently they needed a bit longer than that. MJNA has got to be pressuring AXIM to make some shares available for them to sell to raise capital. I don't think that they will sell a huge amount but certainly enough to launch their business with the legislative improvement that I am expecting.
Lots of questions here that can't go on much longer without being resolved. They certainly can't file the 10K with the derivative liability because they have a billion shares to work with now. Disclosing the share and note status has to be on the table.

[TexasMarvL]

I posted this earlier. Below is Cut/Paste from the most recent Q3 10-Q.

"The lack of Cost of Goods Sold is due to lack of sales of products to customers."

The July press release said product was shipping and that Verséa Ophthalmics had signed 50 Eye doctor offices to use our products.

That is the last update about manufacturing and sales and shipping. Next week will be 5 months since that update.


Q3 10-Q
"Revenue
Revenues from operations recognized for the nine months ended September 30, 2023 and 2022 amounted to $26,659 and $1,314 respectively.
Cost of Revenue from operations recognized for nine months ended September 30, 2023 and 2022 amounted to $0 and $0, respectively. The lack of COGS is
due to lack of sales of products to customers in 2023 and 2022.
Revenues from operations recognized for the three months ended September 30, 2023 and 2022 amounted to $9,581 and $1,314, respectively.
Cost of Revenue from operations recognized for three months ended September 30, 2023 and 2022 amounted to $-0- and $-0-, respectively. The lack of COGS
is due to lack of sales of products to customers in 2023 and 2022."

[carusso]

Haven’t there been several filings?

[mc73]

Very concerning!

[TexasMarvL]

41000 × $0.02 = $820. Lol

When a ticker has less than $1000 traded in one day there was no bump.

AXIM has some legitimate potential but until we hear from AXIM management or we hear from AXIM merchandising partner, Verséa Ophthalmics there is nothing to talk about.

We are fast approaching 5 months of silence from AXIM Management on Sales and manufacturing. FIVE MONTHS.

[mc73]

The question is why did it ever bump up here? Sales are nil, no good news....any ideas?

[SunnyDaze19]

Starting the week above .02.... Good start to the month.

[SunnyDaze19]

Could we see a .03 this week?

[mc73]

Back at 2 cents but why?

[Dean14]

I'm thinking its finally time. 1and 2% er's love to get in as the retail investor runs out of money during the Holidays.

[SunnyDaze19]

incremental increases excite me these days... almost back to .02 unless some shorts pop back up.

[Blue Skys]

The CEO of my first Covid EUA stock got 8 years in the big house! He earned it. False reports about EUA progress via a poster on IHUB while flaunting a new Porsche Turbo S to investors. https://www.justice.gov/criminal/criminal-vns/united-states-v-mark-schena

AXIM played it cool and never promised their EUA that they didn't get and just reported the ongoing progress as it was.

[TexasMarvL]

If History repeats itself the 2023 Annual report for AXIM will be out
April 15th 2024 or
April 22nd 2024

Q1 10-Q 2024 would be out a month later in
May 2024.

AXIM Management was silent ALL of Q3 then proved why they were silent with no sales and no manufacturing and no revenue and no COGS results on the Q3 10-Q.

The Q3 10-Q specifically said the lack of Cost of Goods Sold was due to the lack of sales and manufacturing. We already know that 4 months ago Verséa Ophthalmics had signed up 50 Eye Doctors offices. There were obviously sales to be had. If we had paying customers lined up then we know there was an unfulfilled sales demand. An unfulfilled sales demand must be related to an issue with manufacturing or an issue with the tests or both.

What was not spelled out in the Q3 10-Q was the specific manufacturing issue that caused the lack of sales. In fact we still don't know what happened. Now AXIM has 5 months until the Annual report is due. Will we have 5 more months of silence?

[TexasMarvL]

I'm not good at predicting share counts. I just try to understand what is written in the 10-Q reports.

I do hope we see Q4 as the turning point of this company into cashflow positive territory. However, the last 4 months of silence followed by the Q3 10-Q that proved a lack of sales and manufacturing in Q3 prevent me from feeling positive about AXIM at this time. I will continue to hold my position, but AXIM has to prove they can manufacture the product.

My guess is AXIM will provide a press release or 2 or 3 between now and the Q4 10-Q and END-OF-YEAR report. Otherwise we have a very long wait for news.

[Blue Skys]

I don't believe that all of the convertible instruments have been converted but rather only the variable instruments and the executive note that converts at 1 cent. For example the existing notes that convert at 10 cents are most likely not converted.

AXIM was good enough to explain thie FASB accounting on the page that you reference
"Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period."
Therefore the fully diluted number includes all potential shares including potential conversions and not the actual number of shares existing and converted in the OS.

When I crank through the numbers making some assumptions about conversions I arrive at an OS of 360M shares. That is my guess as to the OS will be when it is next updated on OTC Markets. That is only slightly higher than the number of shares predicted by a very astute squirrel some time back.

What do you think TEX? Do you see the share count adding up as I do?

[TexasMarvL]

Quote from Page 33. "AXIM 2023: Goals and Targeting Positive Cash Flow"


"Our DED business strategy is starting to take off. Looking ahead we plan to:
? Successfully complete our clinical trials to prove the accuracy and ease of use to achieve CLIA waivers.
? Generate positive, peer reviewed reviews by eye care professionals as to the performance and ease of use.
? Penetrate the ophthalmologist and optometrist marketplace through our partner with our industry-changing DED diagnostic technology.
? Identify potential strategic acquisition targets to accelerate our DED diagnostic applications and capabilities expansion.
? Grow our DED business to reach a positive cash flow run rate by the end of 2023 and build its profitability beyond."

33

[TexasMarvL]

A cut/Paste from Page 4 is not a prediction. How do you explain the 478,507,054 number associated with the word "diluted"?


The word "diluted" appears 4 times in the 10-Q.
Twice on Page 4 and
Twice on Page 13.

Here are the two paragraphs cut/pasted from Page 13. I think the word "member" should have been the word "number". I think the 47,298,693 should have been 247,298,693. Also this number $3238,429 was missing a comma.


Cut/paste Quoted:
"Net Loss per Common Share
Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification.
Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially
outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-
dilutive.
There were common share equivalents 254,739,838 at September 30, 2023 and 47,298,693 at December 31, 2022. For the Period ended September 30, 2023
these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. If necessary,
the company would increase authorized shares to honour conversion agreements. The company recognized a derivative short share expense for the three and
nine months ending September 30, 2023 in the amounts of $(432,350) and $3238,429 respectively as a result of authorized shares being insufficient to redeem
convertible securities and notes. This was resolved in Quarter ending September 30, 2023. During the Quarter ended September 30, 2023, the Company
increased the authorized capital from 300,000,000 to 1,000,000,000 shares and therefore there is sufficient authorized capital as of September 30, 2023, results
into no short share derivative liability accrual needed and so reclass the same to additional paid in capital as per ASC 815."

[Blue Skys]

You are a breath of fresh air this beautiful holiday weekend Tex! I'm surprised that you are forecasting that all of the convertible instruments will be converted all at once. I found joy and optimism this Thanksgiving with our 100% Vegetarian meal and Alcohol removed wine. As other investors struggle with low vibrations this day after the holiday we are soaring to new vibrational heights.

[TexasMarvL]

Bottom of Page 4 of the 10-Q seems to indicate almost 500 million shares used up once all the Derivative mess is converted. My PDF reader says it is page 7, but document says page 4.

478,507,054. That's worse than I expected.

If Mr Finney has been building out a manufacturing space as per his contract with the company my guess is a large number of shares will have to pay for that manufacturing space at some point. Cash flow better start soon or 1 Billion shares will be used up rather quickly.


Just search on the word "diluted" which is listed 4 times in the 10-Q.

Weighted average common shares outstanding - basic 232,361,241

Weighted average common shares outstanding - diluted 478,507,054

[Blue Skys]

The variable notes would have the best conversion price if they were converted today during market hours or trivially worse if converted on Friday during market hours. That suggests to me that we will see evidence of conversion at the end of next week. Probably Friday but I could conceive of it being released the following Monday along with a resolution of the insufficient shares derivative liability issue.
Does that make sense or is there new math that I'm missing?

[TexasMarvL]

"Kurty" may be a term of endearment between 2 men who are working closely together to resolve problems. I'm sorry.

Maybe I should not have so quickly jumped to conclusions that "Kurty" was just the wrong way to spell a guy's name who is obviously integral to the success of AXIM going forward. Mr Huemoeller never misspells an important name or company in official documents or press releases. Right?

I'm starting to wonder if Mr Huemoeller types up these official documents using his cell phone. Let's blame it on auto-correct. Let's blame it on AI.

[Dean14]

LoL It all sounds about right finally. All I know is we are closer than we were and speculative stocks are becoming more attractive. Allgood for the Home Team.

[TexasMarvL]

Nothing is resolved until revenue is being generated. The revenue paragraph is all you need to read to understand that AXIM is not getting paid for any tests at this time.

AXIM management is silent because they don't want to talk about their failures to manufacture and ship their products to paying customers.

Mr. Kurt Phinney must have changed his name to Kurty Phinney.


Revenue
Revenues from operations recognized for the nine months ended September 30, 2023 and 2022 amounted to $26,659 and $1,314 respectively.
Cost of Revenue from operations recognized for nine months ended September 30, 2023 and 2022 amounted to $0 and $0, respectively. The lack of COGS is
due to lack of sales of products to customers in 2023 and 2022.
Revenues from operations recognized for the three months ended September 30, 2023 and 2022 amounted to $9,581 and $1,314, respectively.
Cost of Revenue from operations recognized for three months ended September 30, 2023 and 2022 amounted to $-0- and $-0-, respectively. The lack of COGS
is due to lack of sales of products to customers in 2023 and 2022.

[Blue Skys]

So Dean, let me try to schedule from right to left and see if you agree with my timeline.
If the wavier application is to be submitted in 2023 then one would think it would be submitted at least a week before Christmas and other holidays so it should be submitted by December 18.
Certainly Versea would have their team peer review the application since they have applied for a lot of waivers across their sectors with great success judging by a search of the CLIA wavier list. How about if we schedule 2 weeks for AXIM to prepare the application after testing is completed followed by 2 weeks of Versea peer review. That timeline suggests that the actual testing must already be completed and it must have been successful or the 10Q would not have stated that the application will be anticipated in Q4.

Going out on a limb that suggests to me that the manufacturing problem was corrected in Q3 and product can be / has been shipped to larger testing facilities with their own waivers during the current quarter resulting in a kickoff of the revenue ramp from the DED test products.
It seems reasonable to me that early next week after a blast of form 4's and an AS/OS update on OTC Markets we will potentially see an 8K regarding the DED business. If the share issuance eliminates the Derivative Liability, Insufficient Shares and at least one Note then the next set of financial statements could be as heart warming as a snifter of Cognac.

[Blue Skys]

I'm surprised that there is no final resolution in the ATD matter. I was expecting that with an agreement in place that it would be closed out. It must not be resolved yet or JH would undoubtedly have noted it. Perhaps that times to coincide with another related announcement.

Great to see the wavier testing in progress in the current quarter. That suggests that the manufacturing issue was resolved in Q3 as was anticipated by some on the board.

[Dean14]

We plan to file for the
waiver in the fourth quarter of 2023 after conducting a fairly simple comparative clinical study.

On September 19, 2022 the Company announced that it had signed an exclusive global commercialization agreement with Verséa Ophthalmics, LLC, a
business division of Verséa Holdings, Inc. (“Verséa”), is one of the fastest growing U.S. healthcare companies, specialized in the sale and distribution of
diagnostic and therapeutic solutions.
Our tests are considered moderately complex by CLIA. This requires the user of the test to obtain a CLIA certificate of compliance. This is done by filing a
simple application with CMS (Form 116) and paying a fee. However, there are various lab requirements that must be in place first, and there is a considerable
amount of ongoing record keeping that is required, which restricts potential growth of the business.
The FDA allows for a CLIA waivers, and we intend to pursue a waiver for both current tests and all future product offerings. Our scientists have been diligently
making patentable improvements to the tests which will simplify use by the clinician and enhance likelihood of CLIA waiver approval. On September 19, 2022 the Company announced that it had signed an exclusive global commercialization agreement with Verséa Ophthalmics, LLC, a
business division of Verséa Holdings, Inc. (“Verséa”), is one of the fastest growing U.S. healthcare companies, specialized in the sale and distribution of
diagnostic and therapeutic solutions.
Our tests are considered moderately complex by CLIA. This requires the user of the test to obtain a CLIA certificate of compliance. This is done by filing a
simple application with CMS (Form 116) and paying a fee. However, there are various lab requirements that must be in place first, and there is a considerable
amount of ongoing record keeping that is required, which restricts potential growth of the business.
The FDA allows for a CLIA waivers, and we intend to pursue a waiver for both current tests and all future product offerings. Our scientists have been diligently
making patentable improvements to the tests which will simplify use by the clinician and enhance likelihood of CLIA waiver approval. We plan to file for the
waiver in the fourth quarter of 2023 after conducting a fairly simple comparative clinical study. The objective will be to determine whether the AXIM Eye test
system has equal or better simplicity than the other forms of diagnostic testing for DED, which we believe is the case. This study is a key component of the
filing process with the FDA for a Clinical Laboratory Improvement Amendment (CLIA) Certificate of Waiver. We believe that the acquisition of these FDA
510(k) cleared diagnostic products, a waiver and the distribution partnership we have with Versea will allow the business to grow at a rapid pace.
. The objective will be to determine whether the AXIM Eye test
system has equal or better simplicity than the other forms of diagnostic testing for DED, which we believe is the case. This study is a key component of the
filing process with the FDA for a Clinical Laboratory Improvement Amendment (CLIA) Certificate of Waiver. We believe that the acquisition of these FDA
510(k) cleared diagnostic products, a waiver and the distribution partnership we have with Versea will allow the business to grow at a rapid pace.

[Dean14]

https://www.otcmarkets.com/filing/conv_pdf?id=17070264&guid=3RJ-kns94R7-B3h

[Blue Skys]

Well Tex, we have seen the families agenda with their ticker NPTX. Request the 5 day extension, never file the 10Q, let the stock drop to .0001, move to the Expert Market and allow the tucker to be revoked while continuing business as usual . AXIM requested the 5 calendar extension last Tuesday and has not filed as of yet.

[TexasMarvL]

I hesitate to say anything mainly because AXIM management has not said anything about sales and manufacturing for four months.

Against that 4 month wall of silence go over to LinkedIn and look at the Verséa Ophthalmics and Verséa Health posts in the last month. Just focus on the posts and re-posts related to the Verséa Opththalmics division.

On one hand we have a 4 month wall of silence.
On the other side we can see tons of excitement and activity on the sales side.


What does all this mean?


All I'm going to say is that I still own all my shares.
2.2 cents average cost in one account.
3.3 cents average cost in another account.
My extra funds have dried up recently so I have not average down this last month.

What does all this mean?

Nothing really. Until we hear from AXIM it means nothing. On the other hand it should be encouraging to see all the excitement and activity from the sales team.

[TexasMarvL]

Verséa Ophthalmics is still advertising. This article was in "Eyes on Eyecare".

https://hubs.la/Q029jdj50

[Blue Skys]

The MJNA NT 10-Q is out so another week to get receive their 10Q as well. I looked too quickly yesterday and thought it was new. Nevertheless my notes from last Q still apply except that NPTX was not revoked yet so that explains why that was not noted or addressed so I deleted that comment.
MJNA owns 10% of the AXIM common in addition to holding a $4M note that is convertible into 53.8M shares. The description of the AXIM asset is quite flattering.
The table of notes and the prose that follows it is interesting as is the table of insider ownership. Lots of family members that are also present on AXIM. Interesting to see B. Neil Schroeder allowing restricted shares to be cancelled and replaced with unrestricted shares and notes when he migrated from MJNA to AXIM. Its going to be interesting to see how these data correlate with the data in the AXIM 10Q when it drops. One has to integrate the filings from the full set of companies to gain a picture of this enterprise.

[Dean14]

It appeared today the market is turning the corner. The 1and 2 %ers must be cracking their wallets open to feed the sheep. Would think all boats will rise over the next few weeks. Companies will start going from tight lips to loose lips. Hope it lasts thru 2024 JMHO

[Blue Skys]

Well here is the NT 10-Q. https://www.otcmarkets.com/filing/html?id=17054022&guid=ckJ-kWUD04t3dth 10Q will be filed by the 5th calendar date after today so in AXIM speak that means some time before the market opens on Monday. We have seen him use the delay for one day recently and we have more often seen him use the entire 5 days plus weekend time that doesn't count in AXIM Land, so who knows. If there are notes to be converted / being converted that could influence him to move the filing one way or the other. The narrative will be interesting. Always lots of words but waiting to see if any progress is disclosed.

[SunnyDaze19]

Updated overview and troubleshooting guide in September.

insert-text-here Guide

[Dean14]

I think the patents AXIM holds is like a wedding ring to Verséa Ophthalmics . Billionaires are playing games with the stock market and product pricing "inflation" for control of Super AI

[TexasMarvL]

I wonder if there is a date in time where Verséa Ophthalmics has had enough and decides to go in a different direction?

As long as Kurt Phinney is under contract with AXIM, Verséa Ophthalmics is probably signed up for the long term. Kurt Phinney is their guy. He has been a business partner with Doctor Sambursky for a long time. Mr Phinney is paid in AXIM shares so the better AXIM does the better Mr Phinney does. The better Mr Phinney does, the better it is for all of us.


I wait for better days.

[Blue Skys]

I wonder if the year end tax sellers are dead yet. The stock was up over 10% on Friday. It looks like there were more buyers than sellers.
JH apparently had the transfer agent skip the monthly AS update with OTC Markets on Thursday. I had guessed that he would because he has a pattern that is rarely broken of delaying disclosures as long as legally possible. The cat is out of the bag because he filed the new AS on Silver Flume on Nov 18 so what's the big secret? I don't think that there is any rush to make that disclosure on OTC Markets since the shareholder letter listed a series of events the last one being the Nevada SOS update so it seems that everything that he advised shareholders would occur has happened. I have come to believe as I posted earlier that once the majority shareholders voted there was no requirement to mail the letters to investors whose vote was not being solicited. It seems like that chapter is closed and the next chapter must be revealed soon. I have a sense that just about everything that needs to happen with the sister companies and the more distant relative companies is nearly completed. It also looks like this week provided the variable conversion note holders the best note conversion price in the history of the world. Better even than the last few that I had proclaimed as the lock in price. If that is indeed the case and the market cap is as low as horse beating will take it then there should be an 8K released by Monday Nov 27 which is exactly 3 months from the date that JH signed the shareholder letter. There was something about a 3 month window in SEC rules that I read previously but I can't find it again and I asked Tex and he didn't seem to be aware of that.
The real question is will the beaten horse turn out to be us that held or the tax sellers.

[Squirrel Hunter]

Cowboys usually stop beating a horse when they are sure it is dead.

"Forgive me for beating a dead horse. I'm not even sure why the horse is dead but here we are."

[TexasMarvL]

Forgive me for beating a dead horse. I'm not even sure why the horse is dead but here we are.

When market opens on Monday it will have been 4 months since AXIM provided an update on Sales and manufacturing of their only 2 FDA cleared 510K Diagnostics tests.

****** FOUR MONTHS. ******
****** TOTAL SILENCE ******

July 12th, 2023 was the biggest announcement in company history. Shipping of revenue generating product had begun. A small biotech development start-up company was manufacturing and selling Diagnostics tests to their exclusive marketing partner Verséa Ophthalmics to some 50 locations that had been signed up. 50 Locations.


After the biggest announcement in company history??

****** FOUR MONTHS. ******
****** TOTAL SILENCE ******

What happened?

[Dean14]

I think it's all about the patents they each have and they will try to control and expand their various test strips in a big way. They seem to both be waiting on the FDA to catch up with the waiver so they can be done in the office.

[Blue Skys]

They have the investment from the Gates Foundation and old managements resignations and still they are floundering in market cap. I am feeling that there is something going on there with their testing business that has not been fully divulged to investors. I was looking at their reader and thinking about the similarity to AXIM's reader and it occurred to me that both companies deployments may not be dependent on the deployment of a specific reader as I had previously thought. I am considering the possibility that these readers may be generic in performance and am wondering if tests from multiple companies could be performed on each others readers. I would expect the optometry customers to purchase the AXIM branded reader but am wondering if a Drug Store Chain like CVS or Walgreens would need a box of different readers or if they could get their waviers on whatever reader is resident in their facility.

[Dean14]

Yep I think your right. OT LMDX received approval for a patent a couple of days ago with no PR. Seems a lot is going on behind the seen with these companies. They must be afraid to let news out till they can get some wind behind them.